Aim: Although statins have been well documented to induce the regression of thoracic aortic plaques, a similar effect of statins on abdominal aortic plaques has not been observed. We aimed to explore whether a statin in combination with a bisphosphonate was effective in the regression of abdominal aortic plaques, which are more likely to be calcified. Methods: Eighty-seven patients with hypercholesterolemia were assigned to the atorvastatin (ATR) etidronate ( 
Introduction
A high level of low density lipoprotein (LDL) cholesterol is a major risk factor for atherosclerosis. Statins not only have a lipid-lowering effect but also have a regression effect on atherosclerotic plaques in the carotid artery, coronary artery, and thoracic aorta [1] [2] [3] [4] [5] study, we sought to elucidate the effects of a combination of atorvastatin (ATR) and ETD on abdominal and thoracic aortic plaques using magnetic resonance imaging (MRI).
Methods

Study Design
We recruited patients from 11 outpatient practices and one health evaluation and promotion center in the Joetsu area, Niigata Prefecture, Japan. All patients were followed up at Niigata Rosai Hospital. At the start of this trial, we thought that it might be problematic to prescribe bisphosphonate to patients without osteoporosis; therefore, we assigned patients with osteoporosis (bone mineral density (BMD) T score 1.5 SD from the normal sex-specific age-adjusted mean) to the ATR ETD group, and patients without osteoporosis to the ATR group. However, after we assigned 45 patients to the two groups, emerging epidemiological studies showed the inverse correlation between BMD and vascular calcification, and suggested the possibility that therapeutic agents with selective increasing effect on BMD could have a regression effect on vascular calcification 19, 20) . We thesefore thought it was necessary to assess the benefit of bisphosphonate and statin combination therapy not only for osteoporotic patients but also for non-osteoporotic patients.
When doctors plan long-term administration of steroids to patients with diseases such as rheumatoid arthritis, simultaneous prescription of bisphosphonate including ETD is recommended for prevention of steroid-induced osteoporosis. The incidence of adverse events caused by bisphosphonate administration has no difference between patients with and without Fig. 1 . MRI slices of aortas and morphometric analysis. At baseline, 10 slices of the thoracic aorta were obtained at 10 mm intervals above the lower corner of the ninth thoracic vertebrae, and 10 slices of the abdominal aorta were obtained at 10 mm intervals above the upper corner of the fourth lumbar vertebrae. After 12 months of treatment, three contiguous slices for each plaque were obtained. The slice most closely matching that at baseline was selected. The lumen area and total vascular area were calculated from the traced luminal and outer wall boundaries. . After confirming the safety of bisphosphonate administration in non-osteoporotic patients, we additionally assigned 42 patients to the two groups. Patients with osteoporosis were assigned to the ATR group, and patients without osteoporosis to the ATR ETD group at this time.
Patients in the ATR ETD group took ATR 20 mg/day and ETD 400 mg/day for 14 consecutive days every 3 months. Patients in the ATR group took ATR 20 mg/day. The treatment arm was known by patients and clinicians. Atherosclerotic plaques in thoracic and abdominal aortas were analyzed by MRI. Treatment effects were evaluated as percent changes from baseline in maximal vessel wall thickness (Max-VWT), vessel wall area (VWA), and lumen area (LA) of atherosclerotic lesions after 12 months of treatment (Fig. 1) .
Patients
Patients eligible for inclusion were aged 45 years or older, pulse wave velocity ≥ 1800, plaque score 5 with carotid artery echography (these parameters revealed the patients at high risk of atherosclerotic plaques), and LDL cholesterol ≥ 160 mg/dL. Excluded were those patients participating in other investigational trials, those with a history of lipid-lowering drugs or bisphosphonates, or those pregnant or having a severe disease (e.g., renal insufficiency, hepatic insufficiency, terminal disease).
All patients were seen at 3-month intervals by their physicians. Body weight and blood pressure were measured, and blood and urine samples were taken for examination. The results of blood and urine examinations were explained by physicians. When the results were LDL cholesterol 200 mg/dL, triglyceride ≥ 220 mg/dL, and/or BP 140 mmHg, ezetimibe, phybrate, and/or valsartan were initiated, respectively, in both groups. When BMD of the patients with osteoporosis additionally decreased by 0.5 SD or more, or BMD of the patients without osteoporosis became 1.5 SD, physicians prescribed ETD to the ATR group patients, or activated vitamin D3 to the ATR ETD group patients. Doctors treated diabetes at their own discretion. If severe side effects occurred, physicians were to withdraw the medication and remove the patients from the study, but their data were included in the analysis. All patients gave written informed consent, and the study was approved by the Ethics Review Committee of Niigata Rosai Hospital.
Evaluation of VWA, Max-VWT, and LA by MRI and Endpoints MRI was performed using the Magnetom VISION 1.5-T (Siemens AG, Medical Solutions) using a phased-array body array coil. T1-weighted (T1W) and T2-weighted (T2W) images of the thoracic descending and abdominal aortas were obtained using an electrocardiographically gated, breath-hold, double-inversion-recovery, fast-spin-echo sequence, as previously reported 22, 23) . Imaging parameters were repetition time (TR) 2 RR intervals, echo times (TE) 32 ms (T1W) and 76 ms (T2W), 20 cm field of view, 5 mm slice thickness, 12 mm interslice gap, 192 256 acquisition matrix, and T1W 9 echo-train and T2W 33 echo-train. The spatial resolution was 0.78 mm. At baseline, 10 slices of the thoracic and abdominal aortas were obtained at 10 mm intervals above the lower corner of the ninth thoracic vertebrae, and above the upper corner of the fourth lumbar vertebrae, with each covering approximately 10 cm portions of the thoracic aorta below the arch, and of the abdominal aorta above the bifurcation of the common iliac artery (Fig. 1) . Atherosclerotic plaques were defined as clearly identified luminal protrusion with focal wall thickening.
Refording repeat MRI after 12 months of treatment, special attention was paid to matching the images to those at baseline. Because the aortas were located very close to the vertebrae, which do not usually move with respiration or bowel movements, the vertebrae, especially the ninth thoracic and fourth lumbar vertebrae, were used as the most important anatomic landmarks (Fig. 1) . To minimize submillimeter errors in matching the images at different time points, three contiguous slices (no interslice gap) were obtained, and the slice most closely matching that obtained at baseline was selected using several anatomic landmarks (i.e., vertebrae, intercostal and lumbar arteries, pulmonary arteries and veins, and mesenteric arteries). The matching procedure was perfomed by two observers who were blinded to the treatment assignment. The inter-observer agreement for the selection of the slice most closely matching that at baseline was 97% (381 of 393 plaques), and the discrepancy was resolved by consensus.
VWA, Max-VWT, and LA in each slice were measured three times by manual planimetry using the Digital Imaging and Communications in Medicine (DICOM) viewer (Synapse version 3.1.1.), and the averages were used for statistical analysis. The LA and total vascular area were calculated from the traced luminal and outer wall boundaries. The VWA was calculated as total vascular area minus LA. All measurements were performed by one investigator who was blinded to the treatment assignment. In our study, 6 patients were randomly selected for the evaluation of intra-observer variability. The accuracy and reproducibility of this method has previously been reported 2, 3, 5, 24) . Plaque characterization by MRI is based on the signal intensities of plaque on T1W, T2W, and the transverse proton density-weighted (PDW) images 25, 26) . Lipid components are identified as hyperintense on T1W and PDW images and hypointense regions on T2W images. Fibrocellular components are identified as hyperintense regions on all three images. Calcium deposits were identified as hypointense regions on all images; however, the PDW images were omitted to reduce examination time in our study. Total examination time was about 40 min.
We considered the plaques with the greatest Max-VWT in thoracic and abdominal aortas as the representative plaques of a patient. We also measured Max-VWT, VWA, and LA in all plaques. Therapy effects were evaluated by the changes of these parameters in representative plaques as well as by the average changes in all plaques.
The primary endpoint was the change of Max-VWT after 12 months of treatment. Secondary endpoints were the changes of VWA and LA after 12 months of treatment. All endpoints were assessed by an independent committee, whose members were blinded to the patients' treatment assignments. 
Statistical Analysis
Differences between baseline and after 12 months of treatment were evaluated by the paired t test for continuous variables. Differences between the two groups were evaluated by the unpaired t test for continuous variables and by the Chi-square test for categorical variables, because the distributions of all variables in both groups were normal, and their variances in both groups were not significantly different. Correlations between changes in Max-VWT and those in LDL cholesterol levels or other factors were evaluated by multiple regression after univariate analysis. Associations between regression effects on the representative plaques and those on all plaques, and between Max-VWT and VWA, Max-VWT and LA, VWA and LA were examined by linear regression with Pearson's correlation coefficient. A difference of p 0.05 was considered significant. Statistical analysis was performed using Sigma Stat software (SPSS, Chicago, IL). Data are presented as the mean SD. Abbreviations as in Table 3 .
Results
Patients' Characteristics
Between January 2006 and April 2008, 87 patients were assigned to the ATR ETD (n 45) or ATR (n 42) groups ( Table 1) . During the 12-month follow-up, four patients required fibrate therapy (two in each group), and four withdrew because of adverse events (two with gastrointestinal symptoms in the ATR ETD group, one with liver dysfunction and one with general fatigue in the ATR group). There were no significant differences in any parameter between the two groups.
Laboratory Results
ATR ETD and ATR groups reduced LDL cholesterol levels ( 42% and 43%) after 12 months of treatment (p 0.001 vs. baseline for both groups) ( Table 2 ). In addition, other serum lipid levels and risk factors, except systolic blood pressure, were also Data are presented as the mean SD. Abbreviations as in Table 3 .
significantly altered from baseline in both groups; however, changes of these parameters were not significantly different between the two groups.
MRI Results
All patients had thoracic and abdominal aortic plaques analyzed by MRI at baseline. A total of 98 thoracic and 107 abdominal aortic plaques were detected in the ATR ETD group, and 86 thoracic and 102 abdominal plaques in the ATR group. At baseline, there were no differences in Max-VWT, VWA, and LA between the two groups ( Table 3) . After 12 months' treatment, the ATR ETD group reduced Max-VWT ( 15%) and VWA ( 17%) in thoracic aortic plaques (p 0.001), as did the ATR group ( 14% and 16%, P<0.001). Both groups increased LA ( 6%) in thoracic lesions (p 0.001). There were no differences in changes of Max-VWT, VWA, and LA in thoracic lesions between the two groups.
For abdominal lesions, the outcomes were different ( Table 4) . The ATR ETD group reduced Max-VWT ( 14%) and VWA ( 16%) in abdominal aortic plaques (p 0.001), whereas the ATR group did not ( 1%, p 0.958 and 2%, p 0.675). In addition, the ATR ETD group increased LA ( 5%) in abdominal lesions (p 0.001), whereas the ATR group did not (0%, p 0.971). There were significant differences in changes of Max-VWT, VWA, and LA in abdominal lesions (p 0.001) between the two groups. Table 3 and 4 illustrate treatment effects in the representative plaques. We also evaluated treatment effects in all plaques and obtained very similar trends (Table 5 and 6).
As shown in Fig. 2 , changes in representative plaques were tightly correlated with average changes in all plaques in thoracic and abdominal aortas (r values of Max-VWT (0.85), VWA (0.83), and LA (0.73) in thoracic aorta, and 0.89, 0.87 and 0.76 in abdominal aorta). In Fig. 3 , the changes of Max-VWT were significantly correlated with the changes of VWA after treatment (r 0.77 in the thoracic aorta, r 0.74 in abdominal aorta), and changes of MAX-VWT and VWA were significantly negatively correlated with the changes of LA (r 0.69 and r 0.75 in thoracic aorta, r 0.72 and r 0.75 in abdominal aorta). Table 7 summarizes correlations between the changes of Max-VWT in representative plaques and LDL cholesterol levels and other factors. Percent change of Max-VWT in thoracic aortic plaques corre- lated well with the degree of LDL cholesterol reduction (r 0.56), and also with the degree of high sensitivity C-reactive protein (hsCRP) reduction (r 0.50). A weak correlation was found between that in thoracic lesions and the degree of high density lipoprotein cholesterol alteration (r 0.23). While that in abdominal lesions did not correlate with the degrees of LDL cholesterol (r 0.20) and hsCRP reduction (r 0.18), it correlated with age at baseline (r 0.47) and diabetes duration (r 0.39). The addition of ETD to ATR correlated with that in abdominal lesions (r 0.36), but not with that in thoracic lesions (r 0.09). The correlations between changes of Max-VWT in all plaques and LDL cholesterol levels and other factors were similar to Table 7 (data not shown).
Regarding plaque characterization, calcification in the abdominal aorta was detected in 23 (26%) of 87 patients, as compared with 13 (15%) of 87 patients in the thoracic aorta (p 0.0613).
Discussion
Our study demonstrated that 12 months' treatment with 20 mg ATR and 400 mg ETD combination therapy was effective in reducing the serum LDL cholesterol level and plaque size not only in the thoracic but also the abdominal aorta. In contrast, 20 mg ATR therapy reduced serum LDL cholesterol levels and plaque size in thoracic aorta, but failed in the abdominal aorta. This is the first report that the combination of ATR and ETD may be effective in reducing plaques in the abdominal aorta.
In other clinical trials, ATR or simvastatin treatment reduced LDL cholesterol ( 38-47%) 2, 4, 5) , . Our ATR and ATR ETD groups also showed a similar reduction of LDL cholesterol ( 43 and 42%) and Max-VWT in thoracic lesions ( 14 and 15%). In contrast, no reports have demonstrated the effectiveness of any statin in reducing abdominal aortic plaques. Yonemura et al. found a Max-VWT alteration ( 1%) in abdominal lesions (p NS vs. baseline) after treatment with 20 mg ATR 5) . In our study, the ATR group showed a similar alteration ( 1%, p 0.958), whereas the ATR ETD group reduced Max-VWT ( 14%) in abdominal lesions (p 0.001).
In addition, the percent change of Max-VWT in thoracic aortic plaques correlated well with the degrees of LDL cholesterol and hsCRP reduction; however no such correlation was found in abdominal lesions.
Why did these discrepancies between thoracic and abdominal aortic plaques occur ? The main reason is thought to be the differences of plaque constituents between thoracic and abdominal aortas. An autopsy study reported fatty streaks to be more common in the thoracic aorta 6) . In rabbits fed a cholesterol diet, the thoracic aorta had more atheromatous lesions with more cholesterol accumulation than the abdominal aorta 7) . Tribouilloy et al. reported an association between serum LDL cholesterol levels and thoracic aortic plaques by transesophageal echocardiography 27) ; therefore, lipid-lowering therapy is likely to be effective for plaque regression in the thoracic aorta.
Conversely, in the abdominal aorta, calcification and fibrous changes were more common than those in the thoracic aorta and these changes increased with age 6, 8) . Giral et al. found no association between LDL . In our study, the rate of patients who had abdominal aortic calcification (26%) tended to be higher than those with thoracic calcification (15%). The higher prevalence of calcified plaques and fibrous plaques may be the reason why statins are less effective for plaque regression in the abdominal aorta.
ETD is a first generation bisphosphonate that has a weaker effect on the inhibition of bone resorption, but a stronger effect on the prevention of ectopic and vascular calcification than new generation bisphosphonates. ETD inhibits the formation from calcium phosphate to crystals of hydroxyapatite, which cause ectopic and vascular calcification 29) . This effect does not occur with other bisphosphonates. Some clinical studies have evaluated the regression effect of bisphosphonates on vascular calcification and atherosclerotic plaques. Only ETD could show a regression effect 13, 18) , whereas other bisphosphonates only prevented or failed to reduce the progression of these plaques [30] [31] [32] ; therefore, we thought that it was logical to give statins and ETD, which have regression effects on fatty streaks and calcification, respectively, for coexisting lipid and calcification plaques. Calcified atherosclerotic plaques in the abdominal aorta were associated with cardiovascular disease risk factors [9] [10] [11] [12] . It should be carefully evaluated whether the regression of these plaques is actually associated with the prevention of cardiovascular diseases in future trials.
In the present study, we considered plaques with the greatest Max-VWT in thoracic and abdominal aortas as the representative plaques of a patient. If we can evaluate the treatment effect by measuring only two (thoracic and abdominal) representative plaques per patient, it will be a much simpler measurement with fewer errors, and more easily reproducible than by measuring all plaques; therefore, these were assessed in the present study. In the results, changes of Max-VWT, VWA, and LA in representative plaques and those in all plaques showed strong correlations (Fig. 2) , and we thought that the treatment effect could be evaluated by changes in representative plaques.
Next, we considered the change of Max-VWT in representative plaques as the primary endpoint. The changes of Max-VWT, VWA, and LA are very important to evaluate the treatment effect and were also used in previous reports 2, 3, 5) ; however, Fig. 3 showed that the changes of Max-VWT, VWA, and LA were closely associated. Thus, we believe that the change of Max-VWT in representative plaques was the primary endpoint in the present study.
Our study has several limitations. First, it was not a randomized trial. We intentionally assigned the patients to the two groups; therefore, we do not know whether both groups have the same unknown bias which affects plaque regression. Thus, a further trial is ongoing to investigate the effect of ATR ETD on abdominal aortic plaques in patients who were randomly assigned to each group.
Second, we treated a small number of Japanese patients, and the 20-mg dose was used for ATR, because it is the maximum approved dose in Japan. The 20-mg dose is less than the dose (80 mg) in trials in Western countries; therefore, our results using the current dose may not be directly applicable to other ethnic groups.
Conclusion
The present study indicated that a combination of ATR and ETD has potential in the treatment of thoracic and abdominal aortic plaques.
